Equities Analysts Issue Forecasts for XENE Q1 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Xenon Pharmaceuticals in a research report issued on Friday, February 28th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of ($1.32) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $53.00 target price on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.30) EPS and Q4 2026 earnings at ($1.42) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05.

Several other brokerages have also recently issued reports on XENE. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $57.38.

Xenon Pharmaceuticals Price Performance

Shares of Xenon Pharmaceuticals stock opened at $36.02 on Monday. The firm’s fifty day simple moving average is $39.17 and its 200-day simple moving average is $40.30. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of -12.77 and a beta of 1.26. Xenon Pharmaceuticals has a 12 month low of $33.27 and a 12 month high of $47.44.

Insiders Place Their Bets

In related news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares in the company, valued at $1,267,731. This represents a 34.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,492 shares of company stock worth $2,334,969. Corporate insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth about $63,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Xenon Pharmaceuticals by 17.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 191,852 shares of the biopharmaceutical company’s stock valued at $7,521,000 after purchasing an additional 29,169 shares during the last quarter. Woodline Partners LP acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $1,566,000. Vident Advisory LLC acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $212,000. Finally, Two Sigma Advisers LP raised its stake in Xenon Pharmaceuticals by 9.1% in the 4th quarter. Two Sigma Advisers LP now owns 298,700 shares of the biopharmaceutical company’s stock valued at $11,709,000 after purchasing an additional 25,000 shares during the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.